GEN Exclusives

More »

GEN News Highlights

More »
Jun 23, 2010

Biovail and MedGenesis Receive $2.1M Grant for Parkinson Disease Trials

  • Biovail and MedGenesis Therapeutix confirmed the receipt of $2.1 million from the Michael J. Fox Foundation to fund further clinical development of glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson disease.

    GDNF is a naturally occurring growth factor that protects and promotes the survival of dopamine-producing nerve cells, the firms explain. The candidate is being developed by Biovail and MedGenesis through a collaboration agreement announced in January. Parkinson disease is the first GDNF indication the partnership is focused on.

    The GDNF co-development agreement followed on from MedGenesis’ negotiation of an exclusive, worldwide license to the GDNF protein from Amgen for both CNS and non-CNS applications. This deal, also announced in January, gave Amgen a small equity stake in MedGenesis.

    .   


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?